Drug intelligence / Profile preview

LPT-353

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-353 is an incrementally modified drug (IMD) being developed by LitePharmTech as an ophthalmic solution. Currently in the preclinical stage of development, LPT-353 is part of a series of ophthalmic candidates (including LPT-301, LPT-351, LPT-352, and LPT-354) that leverage LitePharmTech's formulation expertise to improve upon existing ophthalmic therapies. As an IMD (개량신약), the product likely features enhancements in solubility, stability, or bioavailability compared to original reference products, aimed at improving therapeutic efficacy or patient compliance. Specific details regarding the active pharmaceutical ingredient and the target ophthalmic indication have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on LPT-353.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-353.

Explore the full profile